Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Nowo rozpoznana białaczka ostre szpikowa (AML), potwierdzona badaniem szpiku kostnego
- •Obecność mutacji FLT3-ITD (potwierdzona badaniem molekularnym)
- •Całkowita remisja choroby potwierdzona w badaniu szpiku (poniżej 5% złośliwych komórek)
- •Wystarczająca liczba białych krwinek i płytek krwi (neutralofile powyżej 1000, płytki powyżej 100)
- •Poprzednie leczenie indukcyjne (1-2 cykle) i konsolidacyjne (do 4 cykli)
- •Możliwość rozpoczęcia leczenia podtrzymującego w ciągu 60 dni od ostatniego cyklu chemioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (64)
University of Alabama - Birmingham
Birmingham, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
John Hopkins School of Medicine
Baltimore, United States
Umass Memorial Health Care Systems
Worcester, United States
John Theurer Cancer Center at Hackensack UMC
Hackensack, United States
Roswell Park Cancer Institute
Buffalo, United States
Weill Cornell
New York, United States
Westchester Medical College
Valhalla, United States
Clinical Research Allicance
Westbury, United States
Novant Health Clinical Research
Charlotte, United States
East Carolina University
Greenville, United States
Spoknwrd Clinical Trials Inc.
Easton, United States
The Methodist Hospital Research Institute
Houston, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Huntsman Cancer Institute
Salt Lake City, United States
Royal Adelaide Hospital
Adelaide, Australia
Austin Health
Australia, Australia
St. Vincent's Hospital Melbourne
Darlinghurst, Australia
The Alfred Hospital
Melbourne, Australia
Royal Perth Hospital
Perth, Australia
Gold Coast University Hospital
Southport, Australia
Westmead Hospital
Sydney, Australia
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Cetus Hospital Dia Oncologia
Minas Gerai, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre Centro Multidisciplinar de Pesquisa
Porto Alegre, Brazil
INCA - Instituto Nacional de Câncer
Rio de Janeiro, Brazil
"Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto CIP - Centro Integrado de Pesquisa"
San Jose Rio Preto, Brazil
Hospital Santa Marcelina
São Paulo, Brazil
ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
São Paulo, Brazil
Peking Union Medical College Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Guangdong Provincial People's Hospital
Guangzhou, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
Sun Yat-sen University Cancer center
Guangzhou, China
The First Affiliated Hosptial of Zhejiang University School of Medicine
Hangzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Zhong Da Hospital, Southeast University
Nanjing, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Huashan Hospital, Fudan University
Shanghai, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
The First Affiliated Hospital of Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Inje University Haeundae Paik Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Yeungnam University Hospital
Daegu, South Korea
National Cancer Center
Goyang-si, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Jeonbuk National University Hospital
Jeonju, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Ulsan University Hospital
Ulsan, South Korea
Trial contact
Contact for Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.